Tremelimumab - MedImmune

Drug Profile

Tremelimumab - MedImmune

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pfizer; Seoul National University Hospital; University College London; University of Maryland Greenbaum Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Hepatocellular carcinoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Phase II Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Urogenital cancer
  • Phase I/II Colorectal cancer; Malignant melanoma; Oesophageal cancer
  • Phase I Diffuse large B cell lymphoma; Gynaecological cancer; Oropharyngeal cancer; Thyroid cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 09 Mar 2018 Samsung Medical Center plans a phase II trial for Head and neck cancer (Combination therapy, Recurrent disease, Metastatic disease, Second-line therapy or greater) in South Korea in March 2018 (NCT03450967)
  • 08 Mar 2018 M.D. Anderson Cancer Center and AstraZeneca plans a phase I trial for Cervical cancer and Vulvovaginal cancer (Combination therapy, Recurrent, Metastatic disease) in USA (NCT03452332), in March 2018
  • 20 Feb 2018 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03275597)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top